NRIX – nurix therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Nurix Therapeutics, Inc. (NASDAQ: NRIX) was upgraded by analysts at Leerink Partnrs to a "hold" rating.
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at Leerink Partners. They set a "market perform" rating and a $16.00 price target on the stock.
Form DEFA14A Nurix Therapeutics, Inc.
Form ARS Nurix Therapeutics, Inc. For: Nov 30
Form DEF 14A Nurix Therapeutics, Inc. For: May 19
Form 4 Nurix Therapeutics, Inc. For: Mar 11 Filed by: Baynes Roy D.
Form 3 Nurix Therapeutics, Inc. For: Mar 11 Filed by: Baynes Roy D.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.